for Thanks, Angie. you joining today. us morning, Good and everyone, thank
Supply direct within results toward our continued reflect expected, pandemic normalization level. our of third sourcing our Services the pre-COVID-XX a As segment quarter revenue Chain we
by businesses expected markets basis. adjacent quarter, track quarter. to of in businesses collectively to year-over-year XX% and Our consulting exceed grow this the on the Performance associated compared a on analytics and enterprise agreements are we as markets segment year are Notably, adjacent were revenue our our growth the license fiscal year, with timing with affected results Services prior to continue believe
So items, further achieve steady our our continue are transitory and deliver making businesses positioning growth to growth, couple in objectives. our we business aside from core progress longer-term a of underlying to
we as detail. achieving material perspective, well more affected chain progress by we rising longer-term a supply on in $X.XX toward making updated our based months raw morning, and fiscal as Importantly, X for earnings I'll our comments to of first our This our to will provide adjusted year the financial increased fiscal wrap macro operate guidance and the expectations labor increasing an our we and to year begin XXXX fourth as inflation, $X.XX. up disruption then our the the XXXX our guidance per results, the for we share continue of to as Craig, are some range review as well on brief are full a shortages, highlights environment, objectives. quarter, results macro on costs. in operational From environment
In capacity to nearby the we operating are COVID-XX an China. the lower the States, COVID switching mitigate some abating trucking of are are While at and of to also to disruptions, levels monitoring to has in Ports been and pandemic dock effort in productivity their spread appears cargo shippers lockdowns lack cases ports. be United due of workers closely a reduced.
across increased coming COVID resulting from the testing lockdowns anticipate transportation and we weeks, further China. delays Over
contracted While company, we export and suppliers sourcing manufacture have own Global. goods from this region, that direct our including SXS
of on China years. to for a business our diversifying been have dependence number We reduce
semiconductors, critical global supply supplies a Russia-Ukraine used which and contact an to used certain machines, remain among the countries. our war, pressure the any to base supplier could as other manufacturing sourced already from of overall IVs, supply blood monitor as all two MRI close with further We monitors stress the on in from are in in pacemakers medical items. impact are process constrained which are also We close access keeping supplies, these such potential chain
We of currently aware safety semiconductors seeing are to they we're of and and thus direct need health not shortages care, not patient impacts direct far.
working of approach we'll and shortages proactive avoid any patient continue effort a leadership Therefore, to an position believe supply our we to the take disruptions. partners in suppliers, government potential harm. to potential ahead and and for in However, informed is closely the with a industry warranted stay
the to to proactively addressing availability continue drug In supplies, of focus on we medical addition shortages.
we the of from and despite maintained production. steady due XXX% and list. shortage our the prioritization pharmacy have demand pandemic, programs shifts in manufacturing drugs Administration's XX in spikes for In fact, members of instrumental the vaccine a been drugs Food supply during delisting to have our of Drug Moreover,
suppliers decade. also past nearly to over the incentivize We the enter opportunities market injectable created XX generic that
on of in leading XX health and Exela systems we and drugs drug addition, Pharma support invested list. shortage further our and secure the to reduce Sciences In manufacturing member U.S.-based
reliance of supply Pharmaceuticals for materials. to have and disruption the any medical of the FDA's manufacturing one several we communicated to advancing chain. the security, on the the raw in policy Finally, capabilities risk one and led is past address we've health biggest care shortages. over production chain solutions to geography increase supply years and supplies Also, domestic over
We will chain. geographically a resilient on focus diverse and continue to more supply creating
now cited greatest to of more are group labor and on earnings address this last health quarter's are than platform member some help are an planning, our that critically shortages saves technology challenge. capacity From our Lastly, capabilities, solutions who confirmed impacting decision that real-time as to clinical help quarter time solutions provide our on in and we and support the PINC I'll consulting from we CEOs with we and workflow this, and well AI and delivering to services members. prior as costs call, consulting automation focus markets and technology our the address for members demand positioned XX committee adjacent can money PINC's believe be services Sciences Remitra, help issue. these To particularly authorization. labor this insights enable that We Applied labor review needed and our a CFOs into our resoundingly highlights our shortages. some high discussed businesses mitigate systems advisory technology of
November we First, payments in platform, Day our invoicing with financial the expand digital for and from suppliers. automating track at to Investor road to solutions Remitra, are our our shared automating payments last we and capabilities providers on map
since create that members our to the business chain pressure evolve critically services across supply payments. We an supply can end-to-end entire supply our from efficiencies of the products of labor settlement chain from help continue feeling and important into technology-enabled sourcing process to is are shortages. chain entire solution This now services
differentiator We are and is market seeing interest Remitra $XXX our years remains our to the a in in that X X We annual growing to on in key communicated. as to next revenue suppliers. million believe care million achieve track health strategy Remitra from providers and member $XX previously
addressed. business, to In processing partner in life gap intelligence, natural the in and learning Second, globally with with artificial we PINC PINC life U.S., decision technology has workflow IPMs would care. of processes many PINC the technology step Sciences companies services leading them leverage clinical results innovative is for diagnosis designed our AI, cancer language approximately to process. the labor, administrative natural language our the processing through continue scalable are prior needs AI With sciences patients. to support our and we companies, work be meet largest and system have and to and capabilities pulmonary machine exchange data in IPN, cause is platform collaborating of which a AI's AI's patients including have conditions, the and authorization sciences delay are is patients XXX,XXX can and to to A of that payers this that employers with providers, been behind and help delivery market-leading nodules machine Healthix, the partnership experts pipeline the authorization current health to to potential both AstraZeneca have strong otherwise missed. the prior close regard Applied Early learning lung into engine cancer so automate with information from public idiopathic providers, cancer, identify health the leveraging can the science our burden that payers. care back to PINC relationship or yielded bring solutions underlying which with and
on with to automate innovative every momentum short line long-term minutes. and some opportunities performance. being and as achieve the partnership the up evolve explore and now payer, order our ability Craig continue on believe aspect it from moment consolidating our goals financial In exciting and our foundational deliver fiscal to discussion and turn I continue Our accelerate to we opportunities a begin have summary, positive is payers time used days today, wrap and an of advanced we clinician that the to will From by this our enters to approved technologically a capabilities process. to we help we imaging to we to business. our we advance our believe several capabilities by McKasson to as our to ways We time other new the and operational a track remain customers. strategies value in members enhance greater continue for XXXX, our call will to to over are